Pishvaian, Michael J <br/><br/>
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Dec 2012 
 - 843-53 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-012-1969-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Benzamides<br/>Chemotherapy, Adjuvant<br/>Cohort Studies<br/>Disease Progression<br/>Drug Administration Schedule<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Imatinib Mesylate<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Neutropenia--chemically induced<br/>Paclitaxel--administration & dosage<br/>Piperazines--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Radiotherapy, Adjuvant<br/>Severity of Illness Index<br/>Treatment Outcome